Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Compound Kushen Injection in advanced colorectal cancer
ChiCTR2400080584Phase 4Recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- Feb 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of compound kushen injection in colorectal cancer (CRC), sponsored by Guang'anmen Hospital. Primary endpoints: Overall survival and Disease-free survival. Started Feb 2024; status: recruiting.
02
Drugs
compound kushen injection
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400080584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080584.